文献速递消化、代谢与肾脏急症

醋酸阿比特龙联合泼尼松龙±恩扎卢胺治疗高危非转移性前列腺癌:STAMPEDE平台两项3期随机对照试验主要结果的荟萃分析

Abiraterone acetate and prednisolone with or without enzalutamide for high-risk non-metastatic prostate cancer: a meta-analysis of primary results from two randomised controlled phase 3 trials of the STAMPEDE platform protocol.
PubMed 文献 · Lancet · 2021-12-23
一句话结论高危非转移性前列腺癌中,ADT联合阿比特龙+泼尼松龙(±恩扎卢胺)较ADT单药显著延长无转移生存(HR 0·53),作者认为应视为新标准治疗。

该荟萃分析汇总STAMPEDE平台两项开放标签3期试验,纳入1974例高危非转移性前列腺癌患者(或高危特征复发),随机接受ADT单药或ADT联合阿比特龙+泼尼松龙(第二项试验再加恩扎卢胺)。中位随访72个月,联合治疗组无转移生存显著优于对照组(HR 0·53,95%CI 0·44-0·64,p<0·0001),6年无转移生存82% vs 69%;总生存、前列腺癌特异性生存、生化失败无生存、无进展生存均显著延长。联合治疗组3级及以上不良事件更多,最常见为高血压和丙氨酸转氨酶升高。作者认为阿比特龙+泼尼松龙应视为该人群的新标准治疗。

要点

  • 高危非转移性前列腺癌(淋巴结阳性,或淋巴结阴性但至少具备T3/T4、Gleason 8-10、PSA≥40 ng/mL中的两项)或高危特征复发者,ADT联合阿比特龙+泼尼松龙较ADT单药显著延长无转移生存(HR 0·53,95%CI 0·44-0·64,p<0·0001)。
  • 6年无转移生存:联合治疗组82%(95%CI 79-85),对照组69%(95%CI 66-72)。
  • 总生存(HR 0·60,95%CI 0·48-0·73,p<0·0001)、前列腺癌特异性生存(HR 0·49,95%CI 0·37-0·65,p<0·0001)、生化失败无生存(HR 0·39,95%CI 0·33-0·47,p<0·0001)、无进展生存(HR 0·44,95%CI 0·36-0·54,p<0·0001)均显著延长。
  • 同时加用恩扎卢胺与单用阿比特龙相比,无转移生存无差异(交互作用HR 1·02,95%CI 0·70-1·50,p=0·91),试验间异质性无统计学意义(I² p=0·90)。
  • 联合治疗组3级及以上不良事件更多:阿比特龙试验37%(169/451)vs 对照组29%(130/455);阿比特龙+恩扎卢胺试验58%(298/513)vs 对照组32%(172/533);最常见为高血压和丙氨酸转氨酶升高。

适用人群与场景

  • 高危非转移性前列腺癌:淋巴结阳性,或淋巴结阴性但至少具备以下两项:肿瘤分期T3或T4、Gleason总和评分8-10、前列腺特异性抗原(PSA)浓度≥40 ng/mL。
  • 高危特征复发:总ADT疗程≤12个月且无治疗间隔≥12个月,PSA浓度≥4 ng/mL且倍增时间<6个月,或PSA浓度≥20 ng/mL,或淋巴结复发。
  • WHO体能状态0-2,无年龄限制;淋巴结阴性者强制接受局部放疗(按当地指南,前列腺及精囊74 Gy分37次或等效大分割方案),淋巴结阳性者鼓励放疗。

诊断标准与关键阈值

  • 高危定义:淋巴结阳性;或淋巴结阴性时满足肿瘤分期T3或T4、Gleason总和评分8-10、PSA浓度≥40 ng/mL中的至少两项。
  • 高危特征复发定义:总ADT疗程≤12个月且无治疗间隔≥12个月,PSA浓度≥4 ng/mL且倍增时间<6个月;或PSA浓度≥20 ng/mL;或淋巴结复发。

处置流程与药物剂量

  • 对照组:ADT单药,可包括手术和促黄体生成素释放激素激动剂及拮抗剂,疗程3年。
  • 联合治疗组:口服醋酸阿比特龙1000 mg每日一次+口服泼尼松龙5 mg每日一次,疗程2年;若省略局部放疗,治疗可持续至疾病进展。
  • 第二项试验的联合治疗组在此基础上加用口服恩扎卢胺160 mg每日一次。
  • ADT疗程3年,联合治疗疗程2年,除非省略局部放疗时治疗可持续至进展。

红旗征与不能漏的情况

  • 联合治疗组3级及以上不良事件:阿比特龙试验37%(169/451)vs 对照组29%(130/455);阿比特龙+恩扎卢胺试验58%(298/513)vs 对照组32%(172/533)。
  • 联合治疗组更常见的高血压:阿比特龙试验5%(23例)vs 对照组1%(6例);阿比特龙+恩扎卢胺试验14%(73例)vs 对照组2%(8例)。
  • 联合治疗组更常见的丙氨酸转氨酶升高:阿比特龙试验6%(25例)vs 对照组<1%(1例);阿比特龙+恩扎卢胺试验13%(69例)vs 对照组1%(4例)。
  • 5级不良事件共7例:对照组无;阿比特龙+泼尼松龙组3例(直肠腺癌、肺出血、呼吸系统疾病各1例);阿比特龙+泼尼松龙+恩扎卢胺组4例(感染性休克2例、猝死2例)。

研究设计与关键结果

  • 研究设计:开放标签3期试验,英国和瑞士113个中心,多臂多阶段平台方案;2011年11月15日至2016年3月31日随机分配1974例患者。
  • 分组:第一项试验对照组455例、联合治疗组459例;第二项试验(含恩扎卢胺)对照组533例、联合治疗组527例。
  • 基线:中位年龄68岁(IQR 63-73),中位PSA 34 ng/mL(14·7-47);774例(39%)淋巴结阳性;1684例(85%)计划接受放疗。
  • 中位随访72个月(60-84),联合治疗组无转移生存事件180例,对照组306例。
  • 主要终点无转移生存:联合治疗组显著延长(中位未达到,IQR不可评估[NE]-NE)vs 对照组(未达到,97-NE;HR 0·53,95%CI 0·44-0·64,p<0·0001);6年无转移生存82%(95%CI 79-85)vs 69%(95%CI 66-72)。
  • 同时使用恩扎卢胺与阿比特龙相比单用阿比特龙,无转移生存无差异(交互作用HR 1·02,95%CI 0·70-1·50,p=0·91);试验间异质性无统计学意义(I² p=0·90)。
  • 总生存:联合治疗组中位未达到(IQR NE-NE)vs 对照组未达到(103-NE);HR 0·60,95%CI 0·48-0·73,p<0·0001。
  • 前列腺癌特异性生存:联合治疗组未达到(NE-NE)vs 对照组未达到(NE-NE);HR 0·49,95%CI 0·37-0·65,p<0·0001;生化失败无生存:联合治疗组未达到(NE-NE)vs 对照组86个月(83-NE);HR 0·39,95%CI 0·33-0·47,p<0·0001;无进展生存:联合治疗组未达到(NE-NE)vs 对照组未达到(103-NE);HR 0·44,95%CI 0·36-0·54,p<0·0001。

证据类型、等级与局限

  • 证据类型:两项3期随机对照试验主要结果的荟萃分析(STAMPEDE平台方案)。
  • 统计效能:为达到90%效能、单侧1型错误率1·25%、目标风险比0·75,对照组需约315个无转移生存事件。
  • 局限:原文未报告局限性。

对床旁实践的改变

  • 作者认为,在高危非转移性前列腺癌男性中,联合治疗较ADT单药与显著更高的无转移生存率相关。
  • 作者认为,醋酸阿比特龙联合泼尼松龙应被视为该人群的新标准治疗。
  • 同时加用恩扎卢胺与单用阿比特龙相比,无转移生存无差异(交互作用HR 1·02,95%CI 0·70-1·50,p=0·91)。
  • 联合治疗组3级及以上不良事件更多,最常见为高血压和丙氨酸转氨酶升高,5级不良事件共7例(对照组0例)。

指南或共识出处

  • STAMPEDE平台方案两项3期随机对照试验主要结果的荟萃分析,发表于Lancet;注册号ClinicalTrials.gov NCT00268476,ISRCTN78818544。

提炼说明

  • 本条依据论文摘要整理;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

BACKGROUND: Men with high-risk non-metastatic prostate cancer are treated with androgen-deprivation therapy (ADT) for 3 years, often combined with radiotherapy. We analysed new data from two randomised controlled phase 3 trials done in a multiarm, multistage platform protocol to assess the efficacy of adding abiraterone and prednisolone alone or with enzalutamide to ADT in this patient population.

METHODS: These open-label, phase 3 trials were done at 113 sites in the UK and Switzerland. Eligible patients (no age restrictions) had high-risk (defined as node positive or, if node negative, having at least two of the following: tumour stage T3 or T4, Gleason sum score of 8-10, and prostate-specific antigen [PSA] concentration ≥40 ng/mL) or relapsing with high-risk features (≤12 months of total ADT with an interval of ≥12 months without treatment and PSA concentration ≥4 ng/mL with a doubling time of <6 months, or a PSA concentration ≥20 ng/mL, or nodal relapse) non-metastatic prostate cancer, and a WHO performance status of 0-2. Local radiotherapy (as per local guidelines, 74 Gy in 37 fractions to the prostate and seminal vesicles or the equivalent using hypofractionated schedules) was mandated for node negative and encouraged for node positive disease. In both trials, patients were randomly assigned (1:1), by use of a computerised algorithm, to ADT alone (control group), which could include surgery and luteinising-hormone-releasing hormone agonists and antagonists, or with oral abiraterone acetate (1000 mg daily) and oral prednisolone (5 mg daily; combination-therapy group). In the second trial with no overlapping controls, the combination-therapy group also received enzalutamide (160 mg daily orally). ADT was given for 3 years and combination therapy for 2 years, except if local radiotherapy was omitted when treatment could be delivered until progression. In this primary analysis, we used meta-analysis methods to pool events from both trials. The primary endpoint of this meta-analysis was metastasis-free survival. Secondary endpoints were overall survival, prostate cancer-specific survival, biochemical failure-free survival, progression-free survival, and toxicity and adverse events. For 90% power and a one-sided type 1 error rate set to 1·25% to detect a target hazard ratio for improvement in metastasis-free survival of 0·75, approximately 315 metastasis-free survival events in the control groups was required. Efficacy was assessed in the intention-to-treat population and safety according to the treatment started within randomised allocation. STAMPEDE is registered with ClinicalTrials.gov, NCT00268476, and with the ISRCTN registry, ISRCTN78818544.

FINDINGS: Between Nov 15, 2011, and March 31, 2016, 1974 patients were randomly assigned to treatment. The first trial allocated 455 to the control group and 459 to combination therapy, and the second trial, which included enzalutamide, allocated 533 to the control group and 527 to combination therapy. Median age across all groups was 68 years (IQR 63-73) and median PSA 34 ng/ml (14·7-47); 774 (39%) of 1974 patients were node positive, and 1684 (85%) were planned to receive radiotherapy. With median follow-up of 72 months (60-84), there were 180 metastasis-free survival events in the combination-therapy groups and 306 in the control groups. Metastasis-free survival was significantly longer in the combination-therapy groups (median not reached, IQR not evaluable [NE]-NE) than in the control groups (not reached, 97-NE; hazard ratio [HR] 0·53, 95% CI 0·44-0·64, p<0·0001). 6-year metastasis-free survival was 82% (95% CI 79-85) in the combination-therapy group and 69% (66-72) in the control group. There was no evidence of a difference in metatasis-free survival when enzalutamide and abiraterone acetate were administered concurrently compared with abiraterone acetate alone (interaction HR 1·02, 0·70-1·50, p=0·91) and no evidence of between-trial heterogeneity (I2 p=0·90). Overall survival (median not reached [IQR NE-NE] in the combination-therapy groups vs not reached [103-NE] in the control groups; HR 0·60, 95% CI 0·48-0·73, p<0·0001), prostate cancer-specific survival (not reached [NE-NE] vs not reached [NE-NE]; 0·49, 0·37-0·65, p<0·0001), biochemical failure-free-survival (not reached [NE-NE] vs 86 months [83-NE]; 0·39, 0·33-0·47, p<0·0001), and progression-free-survival (not reached [NE-NE] vs not reached [103-NE]; 0·44, 0·36-0·54, p<0·0001) were also significantly longer in the combination-therapy groups than in the control groups. Adverse events grade 3 or higher during the first 24 months were, respectively, reported in 169 (37%) of 451 patients and 130 (29%) of 455 patients in the combination-therapy and control groups of the abiraterone trial, respectively, and 298 (58%) of 513 patients and 172 (32%) of 533 patients of the combination-therapy and control groups of the abiraterone and enzalutamide trial, respectively. The two most common events more frequent in the combination-therapy groups were hypertension (abiraterone trial: 23 (5%) in the combination-therapy group and six (1%) in control group; abiraterone and enzalutamide trial: 73 (14%) and eight (2%), respectively) and alanine transaminitis (abiraterone trial: 25 (6%) in the combination-therapy group and one (<1%) in control group; abiraterone and enzalutamide trial: 69 (13%) and four (1%), respectively). Seven grade 5 adverse events were reported: none in the control groups, three in the abiraterone acetate and prednisolone group (one event each of rectal adenocarcinoma, pulmonary haemorrhage, and a respiratory disorder), and four in the abiraterone acetate and prednisolone with enzalutamide group (two events each of septic shock and sudden death).

INTERPRETATION: Among men with high-risk non-metastatic prostate cancer, combination therapy is associated with significantly higher rates of metastasis-free survival compared with ADT alone. Abiraterone acetate with prednisolone should be considered a new standard treatment for this population.

FUNDING: Cancer Research UK, UK Medical Research Council, Swiss Group for Clinical Cancer Research, Janssen, and Astellas.

来源:Lancet,查看原文。版权归原作者所有。

参考来源

  1. Attard G, Murphy L, Clarke NW, et al. Abiraterone acetate and prednisolone with or without enzalutamide for high-risk non-metastatic prostate cancer: a meta-analysis of primary results from two randomised controlled phase 3 trials of the STAMPEDE platform protocol. Lancet. 2021. PMID: 34953525. doi:10.1016/S0140-6736(21)02437-5

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。